Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge

by Team Lumida
January 29, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key takeaways

Powered by lumidawealth.com

  • U.S. life expectancy rose to 79 years in 2024, the highest on record, up 0.6 years YoY
  • Drug-overdose deaths fell more than 26%, the largest annual decline ever recorded by the CDC
  • The drop in fatalities—especially from fentanyl—was the main driver of the longevity rebound
  • Despite gains, the U.S. continues to lag other developed nations on overall life expectancy

What Happened?

Federal data show U.S. life expectancy climbed to a record level in 2024 after collapsing during the Covid-19 pandemic. The Centers for Disease Control and Prevention reported a sharp reduction in overall mortality, led by a historic fall in drug-overdose deaths. Fatal overdoses dropped from about 31 to 23 deaths per 100,000 people in one year, with the steepest declines among teenagers and young adults. Synthetic opioids such as fentanyl, which had driven the crisis, accounted for far fewer deaths than in prior years.

Why It Matters?

The reversal marks a meaningful public-health inflection point after years in which overdoses and pandemic-related deaths dragged U.S. longevity backward. Fewer premature deaths among working-age adults improve labor force stability, healthcare cost trends, and long-term economic productivity. The data also suggest targeted interventions—such as wider naloxone access and expanded treatment infrastructure—can generate measurable population-level impact. However, the U.S. still underperforms peer countries, signaling persistent structural health challenges in chronic disease, prevention, and social care.

What’s Next?

Provisional data into 2025 indicate overdose deaths continue to decline, which could support further gains in life expectancy. The durability of this trend will depend on continued funding for prevention, addiction treatment, and community health programs. Investors and policymakers will also watch whether progress extends beyond overdose mortality into cardiovascular disease and chronic illness—areas that have historically capped U.S. longevity improvements.

Source
Previous Post

“Trump Accounts” Offer $1,000 for Kids—But the Fine Print Makes Them Tricky for Families

Next Post

Global Tech’s AI Spending Wave Accelerates—and the Supply Chain Is Straining

Recommended For You

AI-Discovered Drug Reverses Biological Aging by Up to 6 Years in Mid-Stage Trial, Nature Biotechnology Study Finds

by Team Lumida
1 week ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Insilico Medicine's rentosertib — an AI-designed lung disease drug — reduced biological age by up to six years in a 42-patient mid-stage trial, per a Nature Biotechnology study,...

Read more

Oura Faces Class-Action Over Sleep Data Accuracy — And the Whole Wearables Industry Is Watching

by Team Lumida
1 week ago
person clicking Apple Watch smartwatch

A proposed class-action lawsuit alleges Oura's ring failed to reliably track sleep — raising questions about the gap between wearable health trackers' marketing promises and what their data...

Read more

Employer Healthcare Costs Projected to Rise 9.5% in 2027 — Fourth Consecutive Year of Near-Double-Digit Increases

by Team Lumida
2 weeks ago
doctor holding red stethoscope

Average healthcare costs are projected to reach more than $19,000 per employee in 2027, a 9.5% year-over-year increase, according to Aon. This marks the fourth consecutive year of...

Read more

US Alcohol Consumption Holds at Historic Low as Majority of Americans Now Say Drinking Is Bad for Health

by Team Lumida
4 weeks ago
clear drinking glass with ice cubes

A Gallup poll of 1,200 adults finds 54% of Americans consume alcohol — matching last year's historic low and halting three consecutive annual declines — while 51% now...

Read more

Big Food’s GLP-1 Reckoning: Conagra, Kraft, and Packaged-Food Giants Reformulate for the Not-So-Hungry

by Team Lumida
4 weeks ago
pasta with red sauce on white ceramic round plate

As GLP-1 weight-loss drugs suppress appetite across millions of households, packaged-food companies are retooling recipes, portion sizes, and sensory profiles to win over consumers who eat less but...

Read more

Novo Nordisk Tests Low-Dose Wegovy Pills as Most Patients Already Stick to Smallest Doses

by Team Lumida
4 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has launched a 450-person trial to determine the minimum effective dose of its oral Wegovy pill — a clinically significant shift given that more than two-thirds...

Read more

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
4 weeks ago
doctor holding red stethoscope

A Commonwealth Fund survey of 25,873 adults finds near-universal alarm over health insurance premiums and out-of-pocket costs, even as ACA marketplace premiums surge 58% in 2026 and nearly...

Read more

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
1 month ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
1 month ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
1 month ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more
Next Post
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

Global Tech’s AI Spending Wave Accelerates—and the Supply Chain Is Straining

Coinbase Q2 2024 Earnings Highlights: Diversification Drives Sixth Consecutive Quarter of Positive Adjusted EBITDA

White House Convenes Banks and Crypto Leaders as Coinbase Pulls Support for Key Market-Structure Bill

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Chinese Stock Surge: A Hedge Fund Headache?

Trump Administration Plans Tougher Chip Export Controls to Curb China’s Tech Ambitions

February 25, 2025
China’s Housing Market: Eased Policies Show Promise Amid Economic Struggles

Major NYC Landlord Joel Wiener Files Bankruptcy for Thousands of Apartment Units

May 23, 2025
Binance Aid to Trump Family Crypto Preceded CZ Pardon, Supercharging USD1

Binance Aid to Trump Family Crypto Preceded CZ Pardon, Supercharging USD1

October 30, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018